Skip to contentK
Korro Bio, Inc.
K
KRROKorro Bio, Inc. Q3 2022 · 10-Q
Revenue$0.00$0.00— vs Q3 2021 Net Income-$19.55M-$19.55MN/M vs Q3 2021 EPS Diluted-$0.55-$0.55N/M vs Q3 2021 Operating Income-$20,275,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$11,781,000N/M ended Sep 30, 2022 · filed Nov 8, 2022 · 39 d after period end